GeoVax to Announce Q2 2025 Financial Results and Corporate Update

GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company specializing in the development of vaccines and immunotherapies for infectious diseases and cancer, has announced it will release its second quarter 2025 financial results on July 28, 2025. The announcement will follow the close of U.S. markets, with a subsequent conference call and webcast scheduled for 4:30 p.m. ET to discuss the results and provide a corporate update.

Interested parties can access the live conference call by registering here, with the webcast available in the Investor Relations section of the GeoVax website. Telephone participants are advised to register in advance to receive dial-in details. The webcast will be archived on the company's website for at least 90 days post-event, ensuring wide accessibility.

GeoVax's lead clinical program, GEO-CM04S1, a next-generation COVID-19 vaccine, is currently undergoing three Phase 2 clinical trials. These trials aim to address the needs of immunocompromised patients, evaluate its efficacy as a booster in specific patient populations, and assess its durability among healthy individuals previously vaccinated with mRNA vaccines. Additionally, the company is advancing its oncology program with Gedeptin®, a novel therapy for advanced head and neck cancers, and is developing a vaccine for Mpox and smallpox, with plans to proceed directly to a Phase 3 clinical trial.

This upcoming financial and corporate update is significant for stakeholders and the broader biotech industry, as it provides insights into GeoVax's progress in addressing critical health challenges through innovative vaccine and therapy development. The company's advancements in COVID-19 vaccination and cancer treatment represent potential breakthroughs in medical science, with implications for patient care and public health strategies worldwide.